European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Regenerating Bone defects using New biomedical Engineering approaches

Cel

Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite their considerable disadvantages, including the risk of disease transfer and immunologic rejection, limited supply of bone, costs and complications, allografts and autografts account for more than 80% of total graft volume. Significant growth opportunities exist for synthetic bone grafts in association with mesenchymal stem cells from autologous or allogenic sources as alternatives to biological bone grafts in orthopaedic and maxillofacial surgery. The objectives of REBORNE is to perform clinical trials using advanced biomaterials and cells triggering bone healing in patients. In order to reach this goal, five phase II clinical studies with 20 patients are proposed in 12 clinical centres spread in 8 European countries. Three orthopaedic trials concerning the treatment of long bone fractures and osteonecrosis of the femoral head in adults or children will be conducted using bioceramics, hydrogel for percuteneous injection and stem cells from autologous or allogenic sources. Clinical research will also concern maxillofacial surgery with bone augmentation prior to dental implants and the reconstruction of cleft palates in children. The safety and efficacy of the new therapies will be assessed clinically using X-rays, CT scans and MRI as well as histology of biopsies. These ambitious clinical targets will require research and development efforts from a large consortium of top world class laboratories, SMEs manufacturing biomaterials, GMP-cell producing facilities and surgeons in hospitals as well as the consideration of ethical and regulatory issues. It is expected that REBORNE will expand the competitiveness of Europe through the patenting of new CE-marked bioproducts in the field of regenerative medicine.

Dziedzina nauki

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

FP7-HEALTH-2009-single-stage
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

CP-IP - Large-scale integrating project

Koordynator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Wkład UE
€ 2 121 051,08
Adres
RUE DE TOLBIAC 101
75654 Paris
Francja

Zobacz na mapie
Region
Ile-de-France Ile-de-France Paris
Rodzaj działalności
Research Organisations
Kontakt administracyjny
Marianne Desmedt (Ms.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (23)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 1 Sierpnia 2019

Moja broszura

Permalink: https://cordis.europa.eu/project/id/241879/pl

European Union, 2024